安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
INDICATION ADSTILADRIN is a treatment for adults who have all the following: High-risk non–muscle-invasive bladder cancer (NMIBC) Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy Carcinoma in situ (CIS) with or without other high-grade tumors IMPORTANT SAFETY INFORMATION Who should not receive ADSTILADRIN? Do not receive ADSTILADRIN if you have a sensitivity to
- Ferring Announces Update to NCCN Guidelines Expanding . . .
ADSTILADRIN ® (nadofaragene firadenovec-vncg) is an FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
- What are the most recent research results on Adstiladrin . . .
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer
- Adstiladrin | European Medicines Agency (EMA)
The full indication is: Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours Adstiladrin will be available as a 3 x 10 11 viral particles ml intravesical suspension
- Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ It is used in adults whose cancer does not respond to treatment with bacillus Calmette-Guérin (BCG) and has a high risk of coming back Nadofaragene firadenovec-vncg is also being studied in the treatment of other types of cancer
- Nadofaragene firadenovec-vncg (urinary bladder route)
Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
|
|
|